172 related articles for article (PubMed ID: 35192058)
21. Quality of end-of-life care for patients with metastatic non-small-cell lung cancer in general wards and palliative care units in Japan.
Nakano K; Yoshida T; Furutama J; Sunada S
Support Care Cancer; 2012 Apr; 20(4):883-8. PubMed ID: 22246597
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Late Palliative Care Referral in Children With Cancer.
Kaye EC; Jerkins J; Gushue CA; DeMarsh S; Sykes A; Lu Z; Snaman JM; Blazin L; Johnson LM; Levine DR; Morrison RR; Baker JN
J Pain Symptom Manage; 2018 Jun; 55(6):1550-1556. PubMed ID: 29427739
[TBL] [Abstract][Full Text] [Related]
23. Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).
Vergnenègre A; Hominal S; Tchalla AE; Bérard H; Monnet I; Fraboulet G; Baize N; Audigier-Valette C; Robinet G; Oliviero G; Le Caer H; Thomas P; Gérinière L; Mastroianni B; Chouaïd C;
Lung Cancer; 2013 Nov; 82(2):353-7. PubMed ID: 23932456
[TBL] [Abstract][Full Text] [Related]
24. PALLiON - PALLiative care Integrated in ONcology: study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care.
Hjermstad MJ; Aass N; Andersen S; Brunelli C; Dajani O; Garresori H; Hamre H; Haukland EC; Holmberg M; Jordal F; Krogstad H; Lundeby T; Løhre ET; Mjåland S; Nordbø A; Paulsen Ø; Schistad Staff E; Wester T; Kaasa S; Loge JH
Trials; 2020 Apr; 21(1):303. PubMed ID: 32241299
[TBL] [Abstract][Full Text] [Related]
25. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy during the last 30 days of life and the role of palliative care referral, a single center experience.
Woldie I; Elfiki T; Kulkarni S; Springer C; McArthur E; Freeman N
BMC Palliat Care; 2022 Feb; 21(1):20. PubMed ID: 35125092
[TBL] [Abstract][Full Text] [Related]
27. Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
Goldwasser F; Vinant P; Aubry R; Rochigneux P; Beaussant Y; Huillard O; Morin L
Cancer; 2018 Jul; 124(14):3044-3051. PubMed ID: 29742292
[TBL] [Abstract][Full Text] [Related]
28. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
[TBL] [Abstract][Full Text] [Related]
29. First referral to an integrated onco-palliative care program: a retrospective analysis of its timing.
Barth C; Colombet I; Montheil V; Huillard O; Boudou-Rouquette P; Tlemsani C; Alexandre J; Goldwasser F; Vinant P
BMC Palliat Care; 2020 Mar; 19(1):31. PubMed ID: 32164672
[TBL] [Abstract][Full Text] [Related]
30. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
32. Palliative care referral and associated outcomes among patients with cancer in the last 2 weeks of life.
Ledoux M; Rhondali W; Lafumas V; Berthiller J; Teissere M; Piegay C; Couray-Targe S; Schott AM; Bruera E; Filbet M
BMJ Support Palliat Care; 2019 Mar; 9(1):e16. PubMed ID: 26399699
[TBL] [Abstract][Full Text] [Related]
33. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
Durbin SM; Zubiri L; Niemierko A; Bardia A; Sullivan RJ; McEwen C; Mulvey TM; Allen IM; Lawrence DP; Cohen JV; Hochberg EP; Ryan DP; Petrillo LA; Reynolds KL
Oncologist; 2021 Jan; 26(1):49-55. PubMed ID: 33044765
[TBL] [Abstract][Full Text] [Related]
35. Palliative care and psychosocial care in metastatic non-small cell lung cancer: factors affecting utilisation of services and impact on patient survival.
Duggan KJ; Wiltshire J; Strutt R; Boxer MM; Berthelsen A; Descallar J; Vinod SK
Support Care Cancer; 2019 Mar; 27(3):911-919. PubMed ID: 30066201
[TBL] [Abstract][Full Text] [Related]
36. Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
Sanchis-Borja M; Ricordel C; Chiappa AM; Hureaux J; Odier L; Jeannin G; Descourt R; Gervais R; Monnet I; Auliac JB; Chouaïd C
Lung Cancer; 2020 May; 143():36-39. PubMed ID: 32200139
[TBL] [Abstract][Full Text] [Related]
37. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
Hubbeling HG; Schapira EF; Horick NK; Goodwin KEH; Lin JJ; Oh KS; Shaw AT; Mehan WA; Shih HA; Gainor JF
J Thorac Oncol; 2018 Apr; 13(4):550-558. PubMed ID: 29378267
[TBL] [Abstract][Full Text] [Related]
38. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal symptoms and temporal trends in palliative care, palliative radiotherapy, and anti-cancer treatment near end of life among patients with metastatic cancer.
Chen JJ; Shin KY; Hong PJ; Hertan LM; Krishnan MS; Roldan CS; Huynh MA; Spektor A; Balboni TA
Ann Palliat Med; 2022 Aug; 11(8):2646-2657. PubMed ID: 35815448
[TBL] [Abstract][Full Text] [Related]
40. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
